Patterns of Breast Cancer Locoregional Relapse, Metastasis, and Subtypes in Ghana

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Dec 2

PMID 39623313

Authors

Gloria Agyekum Boaitey

Rachel Martini

Brian Stonaker

Ernest Osei Bonsu

Ernest Adjei

Ishmael Kyei

Mavis Bobie Ansah

Lisa Newman

Christian Obirikorang

Melissa B Davis

Linda Ahenkorah Fondjo

Affiliations

Soon will be listed here.

Abstract

Background: Significant advances have been made in targeted therapeutics and systemic therapy regimens for breast cancer (BC) treatment over the past decade. Tumour cells can however remain in the body, leading to locoregional relapse and/or metastasis. Subtypes of BC have distinct prognostic effects and have been linked to varying risks of early locoregional relapse and metastases, response to treatment, and overall survival. Most Low- and middle-income countries (LMICs) have no registries of BC locoregional relapse and metastasis.

Methods: This study comprehensively reviewed, a 3-year retrospective single-centre data of female BC visiting the Komfo Anokye Teaching Hospital (KATH), Ghana to determine the prevalence of locoregional relapse and metastasis across our patient population. Prevalence of metastasis among the various BC subtypes was also determined.

Results: Prevalence of BC locoregional relapse and metastasis were 3.4% and 47.6% respectively. For BC patients with documented locoregional relapse (N = 36), 27.8% (CI = 15.8 - 44.0%) had relapse to the contralateral breast, 41.7% (CI = 27.1 - 57.8%) had relapse to the ipsilateral breast, and 30.6% (CI = 18.0 - 46.9%) had relapse to regional lymph nodes. For BC patients with documented metastasis (N = 503), 151 (30%) had multiple organs involvement, 141 (28%) had lung metastases, 80 (16%) had bone metastases, 45 (9%) had liver metastases, 16 (3%) had brain metastases and 70 (14%) had other metastases (ovary, uterus, spleen, peritoneum, or distant lymph nodes). Basal subtype was the most common subtype (n = 82, 41%), followed by Luminal A (n = 69, 34.5%), HER2+ (n = 37, 18.5%) and Luminal B (n = 12, 6%). Basal subtypes had the most metastasis (35%), with multiple metastasis being the most prevalent (13%).

Conclusion: Close to half of the patients (46%) presented with metastatic BC. BC subtypes could influence the specific metastatic site. The most common BC subtype was the Basal subtype and had the most metastases (35%), with multiple metastasis being the most prevalent (13%). These findings should serve as a guide in the management of patients to enhance early prediction and detection of locoregional relapse and metastasis for improved overall treatment outcomes.

References

Anie H, Yarney J, Sanuade O, Awasthi S, Ndanu T, Parekh A . Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana. JCO Glob Oncol. 2021; 7:965-975. PMC: 8457842. DOI: 10.1200/GO.20.00664. View

Dilara Savci-Heijink C, Halfwerk H, Hooijer G, Horlings H, Wesseling J, van de Vijver M . Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 2015; 150(3):547-57. PMC: 4383810. DOI: 10.1007/s10549-015-3352-0. View

Vanderpuye V, Grover S, Hammad N, PoojaPrabhakar , Simonds H, Olopade F . An update on the management of breast cancer in Africa. Infect Agent Cancer. 2017; 12:13. PMC: 5307840. DOI: 10.1186/s13027-017-0124-y. View

Eng L, Dawood S, Sopik V, Haaland B, Tan P, Bhoo-Pathy N . Ten-year survival in women with primary stage IV breast cancer. Breast Cancer Res Treat. 2016; 160(1):145-152. DOI: 10.1007/s10549-016-3974-x. View

Muddather H, Faggad A, Elhassan M . Relapse-free survival in Sudanese women with non-metastatic breast cancer. Glob Epidemiol. 2023; 4:100082. PMC: 10445990. DOI: 10.1016/j.gloepi.2022.100082. View

Ignatov A, Eggemann H, Burger E, Ignatov T . Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol. 2018; 144(7):1347-1355. DOI: 10.1007/s00432-018-2644-2. View

Colleoni M, Sun Z, Price K, Karlsson P, Forbes J, Thurlimann B . Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol. 2016; 34(9):927-35. PMC: 4933127. DOI: 10.1200/JCO.2015.62.3504. View

Yu Z, Song M, Chouchane L, Ma X . Functional Genomic Analysis of Breast Cancer Metastasis: Implications for Diagnosis and Therapy. Cancers (Basel). 2021; 13(13). PMC: 8268362. DOI: 10.3390/cancers13133276. View

Kennecke H, Yerushalmi R, Woods R, Chon U Cheang M, Voduc D, Speers C . Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010; 28(20):3271-7. DOI: 10.1200/JCO.2009.25.9820. View

10.

Gyedu A, Gaskill C, Boakye G, Abdulai A, Anderson B, Stewart B . Differences in Perception of Breast Cancer Among Muslim and Christian Women in Ghana. J Glob Oncol. 2018; 4:1-9. PMC: 6180842. DOI: 10.1200/JGO.2017.009910. View

11.

Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L . Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018; 5(2):77-106. PMC: 6147049. DOI: 10.1016/j.gendis.2018.05.001. View

12.

Phakathi B, Nietz S, Cubasch H, Dickens C, Dix-Peek T, Joffe M . Survival of south african women with breast cancer receiving anti-retroviral therapy for HIV. Breast. 2021; 59:27-36. PMC: 8209274. DOI: 10.1016/j.breast.2021.05.014. View

13.

Akuoko C, Armah E, Sarpong T, Quansah D, Amankwaa I, Boateng D . Barriers to early presentation and diagnosis of breast cancer among African women living in sub-Saharan Africa. PLoS One. 2017; 12(2):e0171024. PMC: 5305236. DOI: 10.1371/journal.pone.0171024. View

14.

Adisa A, Arowolo O, Akinkuolie A, Titiloye N, Alatise O, Lawal O . Metastatic breast cancer in a Nigerian tertiary hospital. Afr Health Sci. 2011; 11(2):279-84. PMC: 3158525. View

15.

Chen W, Hoffmann A, Liu H, Liu X . Organotropism: new insights into molecular mechanisms of breast cancer metastasis. NPJ Precis Oncol. 2018; 2(1):4. PMC: 5871901. DOI: 10.1038/s41698-018-0047-0. View

16.

Xiao W, Zheng S, Yang A, Zhang X, Zou Y, Tang H . Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. Cancer Manag Res. 2018; 10:5329-5338. PMC: 6225920. DOI: 10.2147/CMAR.S176763. View

17.

Chen M, Sun H, Zhao Y, Fu W, Yang L, Gao S . Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis. Sci Rep. 2017; 7(1):9254. PMC: 5569011. DOI: 10.1038/s41598-017-10166-8. View

18.

Thomas A, Kidwell K, Oppong J, Adjei E, Osei-Bonsu E, Boahene A . Breast Cancer in Ghana: Demonstrating the Need for Population-Based Cancer Registries in Low- and Middle-Income Countries. J Glob Oncol. 2017; 3(6):765-772. PMC: 5735963. DOI: 10.1200/JGO.2016.006098. View

19.

Courtney D, Davey M, Moloney B, Barry M, Sweeney K, McLaughlin R . Breast cancer recurrence: factors impacting occurrence and survival. Ir J Med Sci. 2022; 191(6):2501-2510. PMC: 9671998. DOI: 10.1007/s11845-022-02926-x. View

20.

Wang R, Zhu Y, Liu X, Liao X, He J, Niu L . The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. 2019; 19(1):1091. PMC: 6852913. DOI: 10.1186/s12885-019-6311-z. View